The portfolio of Robert Karr�� Joho Capital currently lists 16 stocks, 2 of them new, a total value of $1.33 billion, and a quarter-over-quarter turnover of 5%. The portfolio is weighted with top three sectors: technology at 66.2%, consumer defensive 18.41% and healthcare at 7.6%. According to the GuruFocus Score Board of Gurus, the stocks bought by Robert Karr in the past 12 months have an average return of 79.33%. In the third quarter of 2013, Robert Karr was actively reducing his top holdings. Here�� a look at four of them, starting with Baidu Inc. (BIDU), the Chinese language internet search provider incorporated in the Cayman Islands in January 2000. Up 52% since January, Baidu Inc. has had an annual revenue growth of 65.70% over the past 5 years.
Baidu Inc. (BIDU)
Impacts Portfolio: -3.74%
Shares Owned: 1,830,950
Up 65% over 12 months, Baidu Inc. has a market cap of $55.41 billion; its shares were traded at around $158.46 with a P/E ratio of 40.00. The company does not pay a dividend.
Hot Building Product Stocks To Buy For 2015: SWS Group Inc.(SWS)
SWS Group, Inc., a diversified financial services holding company, provides a range of investment and commercial banking, and related financial services to individual, corporate, and institutional investors, as well as broker/dealers, governmental entities, and financial intermediaries in the United States. It operates in four segments: Clearing, Retail, Institutional, and Banking. The Clearing segment provides clearing and execution services for general securities broker/dealers, bank affiliated firms, and firms specializing in high volume trading. The Retail segment offers retail securities products and services, such as equities, mutual funds, and fixed income products; insurance products; and managed accounts. The Institutional segment provides securities lending, investment banking and public finance, fixed income sales and trading, proprietary trading, and agency execution services to institutional customers. The Banking segment offers various banking products and se rvices, including certificates of deposit, money market accounts, interest-bearing demand accounts, savings accounts, federal home loan bank advances, federal funds purchased, and non interest-bearing demand accounts, as well as one to four family residential loans and construction loans, lot and land development loans, commercial real estate loans, multi family loans, commercial loans, and consumer loans. SWS Group, Inc. was founded in 1972 and is headquartered in Dallas, Texas.
Advisors' Opinion:- [By Tim Melvin]
SWS Group (SWS) also catches my eye at the current valuation. The Dallas-based company is in the brokerage, investment banking and banking business in the Southwest. They struggled with losses at the banking subsidiary and eventually had to find a capital infusion. They ended up borrowing $100 million from noted investors Gerald Ford and Robert Bass. The core brokerage and investment banking business are well positioned and should do well over the next few years. I wouldn�� be shocked if this firm was eventually sold off, with Mr. Ford keeping the banking assets and selling the brokerage and I-Bank units to a larger firm. With the stock trading at just 65% of book value, the long-term potential is very high for this stock.
Top Defensive Companies To Own In Right Now: Royal Bank Of Canada(RY)
Royal Bank of Canada provides personal and commercial banking, wealth management services, insurance, corporate and investment banking, and transaction processing services under the RBC name worldwide. Its Canadian Banking segment offers personal financial services, business financial services, and cards and payment solutions. The company?s Wealth Management segment provides wealth and asset management, and estate and trust services to affluent and high net worth clients through distributors, as well as directly to institutional and individual clients in Canada, the United States, Europe, Asia, and Latin America. Its Insurance segment provides various life and health insurance, including universal life, accidental death and critical illness protection, disability, long-term care insurance, and group benefits; and property and casualty insurance comprising home, auto, and travel insurance, as well as wealth accumulation solutions; and reinsurance products through retail ins urance branches, call centers, independent insurance advisors and travel agencies, financial institutions, and career sales force. The company?s International Banking segment offers various financial products and services to individuals, business clients, and public institutions in the U.S. and Caribbean. This segment also provides global custody, fund and pension administration, securities lending, shareholder services, analytics, and other related services to institutional investors. Royal Bank of Canada?s Capital Markets segment engages in the trading and distribution of fixed income, foreign exchange, equities, commodities, and derivative products for institutional, public sector, and corporate clients; and involves in investment banking, debt and equity origination, advisory services, corporate lending, private equity, and client securitization businesses. The company was founded in 1864 and is headquartered in Toronto, Canada.
Advisors' Opinion:- [By Will Ashworth]
CM Rating: 7
Royal Bank of Canada (RY)Dividend Yield: 3.9%
Royal Bank of Canada (RY) is having an excellent 2013. Its adjusted net income for the first nine months of the year through the end of July was up 12.3% to C$6.3 billion, and is expected to grow by 8.7% in Q4 to C$2.2 billion.
- [By Eric Volkman]
The partnership was brought to market by book-running managers JPMorgan Chase unit J.P. Morgan, Bank of America's (NYSE: BAC ) Merrill Lynch, Credit Suisse (NYSE: CS ) ,�Citigroup (NYSE: JPM ) , Barclays, Morgan Stanley, Royal Bank of Canada's (NYSE: RY ) RBC Capital Markets, and the securities arm of Deutsche Bank (NYSE: DB ) .
Top Defensive Companies To Own In Right Now: Rockwell Medical Technologies Inc.(RMTI)
Rockwell Medical Technologies, Inc. manufactures, sells, and distributes hemodialysis concentrate solutions and dialysis kits primarily in the United States, Latin America, Asia, and Europe. The company?s hemodialysis product duplicates kidney function in patients with failing kidneys, known as end stage renal disease, an advanced stage of chronic kidney disease; and dialysis solutions are used to maintain life, remove toxins, and replace nutrients in the dialysis patient?s bloodstream. Its products include Renal Pure and CitraPure liquid acid concentrate, Dri-Sate dry acid concentrate and mixing systems, RenalPure powder bicarbonate concentrate, and SteriLyte liquid bicarbonate concentrates; and various ancillary products comprising blood tubing, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts, and other supplies. The company also has a license to manufacture and sell soluble ferric pyrophosphate (SFP), a Phase III clinical trial p roduct to improve the treatment of dialysis patients with iron deficiency. Rockwell Medical Technologies sells its products to domestic hemodialysis providers through direct sales people and independent sales representation companies, as well as through independent sales agents and distributors internationally. The company was founded in 1995 and is based in Wixom, Michigan.
Advisors' Opinion:- [By John Udovich]
Small cap dialysis stock Rockwell Medical Inc (NASDAQ: RMTI) looks set to decline when the market opens after Brean Capital initiated coverage with a sell rating and a price target of $4.00, meaning it might be time to take a closer look at what is going on with the stock along with�the performance of large cap dialysis stocks DaVita Healthcare Partners (NYSE: DVA)�and Fresenius Medical Care (NYSE: FMS) along with small cap dialysis stocks NxStage Medical, Inc (NASDAQ: NXTM).�
- [By Roberto Pedone]
Rockwell Medical (RMTI) manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the U.S. and internationally. This stock closed up 5.3% to $5.17 in Tuesday's trading session.
Tuesday's Range: $4.89-$5.25
52-Week Range: $3.16-$8.59
Tuesday's Volume: 1.15 million
Three-Month Average Volume: 1.26 millionFrom a technical perspective, RMTI bounced sharply higher here right above some near-term support levels at $4.81 to $4.65 with decent upside volume. This move is quickly pushing shares of RMTI within range of triggering a major breakout trade. That trade will hit if RMTI manages to take out its 200-day moving average at $5.24 and then once it clears more near-term resistance at $5.94 with high volume.
Traders should now look for long-biased trades in RMTI as long as it's trending above some key near-term support levels at $4.81 to $4.65 and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.26 million shares. If that breakout triggers soon, then RMTI will set up to re-test or possibly take out its next major overhead resistance levels at $8 to $8.50.
- [By Jake L'Ecuyer]
Rockwell Medical (NASDAQ: RMTI) was also down, falling 19.90 percent to $10.80 after Brean Capital initiated the company at a Sell rating and a $4 price target.
Top Defensive Companies To Own In Right Now: Auxilio Inc (AUXO)
Auxilio, Inc. (Auxilio), incorporated on August 29, 1995, is engaged in the business of providing fully outsourced print management services to the healthcare industry. The Company is engaged in the business of providing fully-outsourced managed print services to the healthcare industry, working exclusively with hospitals throughout the United States. It provides solutions, a program and savings. It helps hospitals and health systems reduce expenses and create manageable, dependable document image management programs by managing their back-office processes. The process is initiated through a detailed assessment. The assessment is a strategic, operational and financial analysis that is performed at the customer�� premises using a combination of processes and technology for data collection and report generation. The Company�� customers include hospitals and integrated health delivery networks (IDN). Its subsidiaries include Auxilio Solutions, Inc. and e-Perception Technologies, Inc.
The Company helps hospitals and health systems to create image management programs by managing their back-office processes. The process is initiated through a detailed Image Management Assessment (IMA). The IMA is a strategic, operational and financial analysis that is performed at the customer�� premises using a combination of processes and Web-based technology for data collection and report generation. After the assessment and upon engagement, it charged the customer on a per print basis.
The Company competes with Xerox, Canon, Konica Minolta, Ricoh and Sharp.
Advisors' Opinion:- [By CRWE]
Today, AUXO surged (+3.26%) up +0.030 at $.950 with�200 shares in play thus far (ref. google finance Delayed: 9:30AM EDT August 23, 2013).
AUXILIO, Inc. previously reported financial results for its quarter ended June 30, 2013.
For the three months ended June 30, 2013, AUXILIO reported that recurring service revenues increased by $1.4 million from new contracts closed between May 2012 and April 2013; however revenues were $9.8 million, a decrease of 8% when compared to revenues of $10.7 million in the same period of 2012, due to a drop in equipment revenue. Equipment sales were $800,000 as compared to $3.1 million for the same period in 2012. Cost of revenues were $8.2 million for the three months ended June 30, 2013, as compared to $9.3 million for the same period in 2012. This drop was due to the drop in equipment sales offset by additional staffing and service costs from the higher recurring service revenue. Gross profit for the second quarter of 2013 was $1.6 million, or 17% of sales, compared to $1.4 million, or 13% of sales, for the same period of 2012. This improvement is a direct result of the large growth in new facilities that we added in 2012 coupled with the reduction in costs as AUXILIO�� program matures within these new accounts.
Top Defensive Companies To Own In Right Now: Array BioPharma Inc.(ARRY)
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases in North America, Europe, and the Asia Pacific. Its programs under development include ARRY-520, a kinesin spindle protein inhibitor in Phase 2 clinical trial for patients with multiple myeloma; ARRY-614, a p38/Tie-2 dual inhibitor in Phase 1 clinical trial for patients with myelodysplastic syndrome; ARRY-380, a HER2 inhibitor in Phase 1 clinical trial for breast cancer; ARRY-797, a p38 inhibitor in Phase 2 clinical trial for pain; and ARRY-502, a CRTh2 antagonist in Phase 1 clinical trial for allergic inflammation. The company?s partnered drugs in clinical development comprise Selumetinib and AZD8330 MEK inhibitors for cancer in Phase 2 trial; MEK162 and MEK300 MEK inhibitors for cancer in Phase 2 trial; Danoprevir, a Hepatitis C virus protease inhibitor in Phase 2 trial; ARRY-543, a HER2/EGFR inhibitor in Phase 2 trial for solid tumors; and LY2603618, a ChK-1 inhibitor in Phase 2 trial for cancer. Its partnered drugs in clinical development also include AMG 151, a glucokinase activator in Phase 1b trial for Type 2 diabetes; GDC-0068, a AKT inhibitor in Phase 1b trial for cancer; VTX-2337, a toll-like receptor in Phase 1b trial for cancer; VTX-1463, a toll-like receptor in Phase 1b trial for allergy; ARRY-382, a cFMS inhibitor in Phase 1 trial for cancer; and ARRY-575 and GDC-0425, which are ChK-1 inhibitors in Phase 1 trial for cancer. The company has collaborations with Amgen, Inc.; ASLAN Pharmaceuticals Pte Ltd.; AstraZeneca, PLC; Celgene Corporation; Genentech, Inc.; Novartis International Pharmaceutical Ltd.; InterMune, Inc.; Eli Lilly and Company; and VentiRx Pharmaceuticals, Inc for the development and commercialization of the partnered drugs. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.
Advisors' Opinion:- [By John Udovich]
Biotech and the cancer treatment segment of the biotech market has been a hot area for some time with important cancer stocks like large cap Celgene Corporation (NASDAQ: CELG) and small caps�Array BioPharma (NASDAQ: ARRY), Cancer Genetics Inc (NASDAQ: CGIX), EXACT Sciences Corporation (NASDAQ: EXAS) and�MetaStat Inc (OTCMKTS: MTST) all producing a steady flow of important news�for investors this week or in recent weeks. Consider the following:
- [By Sean Williams]
What: Shares of Array BioPharma (NASDAQ: ARRY ) , a biopharmaceutical company focused on the development of small molecule drugs for the treatment of cancer and inflammatory diseases, soared as much as 29% after the company reported positive phase 2 data on ARRY-502, an experimental drug designed to treat mild to moderate persistent allergic asthma.
- [By Keith Speights]
Breathing easier
Array BioPharma (NASDAQ: ARRY ) shares climbed nearly 18% this week. The company announced positive results from a phase 2 study of its experimental asthma drug ARRY-502. - [By Dan Carroll]
Array's phase 2 study pays off big
It's tough to find a stock anywhere on the market that had as good a week as Array BioPharma (NASDAQ: ARRY ) . Shares of the biotech picked up nearly 17.8% on the week, part of a 63.5% gain year-to-date. The company's developmental drug to treat persistent allergic asthma, ARRY-502, hit the right marks in improving patient lung function in phase 2 trial results. Even better for investors, Array CEO said several other health companies have shown interest to help the company in development of ARRY-502.
Top Defensive Companies To Own In Right Now: Octagon 88 Resources Inc (OCTX)
Octagon 88 Resources, Inc., incorporated on June 9, 2008, is a development-stage oil and gas company. The Company has acquired light and conventional heavy oil assets in Northern Alberta. On Jan 22, 2013, the Company launched the Conventional Oil Production Division by entering into a purchase agreement to acquire its share in the Red Earth Area, which consists of four contiguous sections of P&NG leases, a ( 40 API) Keg River formation with P3 reserves of 1.2 Mill barrels light sweet crude oil recoverable.
On December 24, 2012, the Company acquired a 22% interest of CEC North Star Energy Ltd. (North Star). On January 23, 2013, the Company acquired a 10% interest in North Star.
Advisors' Opinion:- [By Jonathan Yates]
For investors looking for a play, small cap firms operating in the oil and natural gas sector in Canada, such as Octagon 88 (OTC: OCTX), Americas Petrogas (OTC: APEOF), and Connacher Oil and Gas (OTC: CLLZF) could draw attention.
- [By Jonathan Yates]
There has been a great deal of concern about the United States suffering from a "lost generation" as Japan has now for several. For investors in oil, this has certainly not been the case: A recent article in The Wall Street Journal noted that oil has risen 310% (Brent Crude) over the last decade. The future looks equally promising for investments in the sector such as ConocoPhillips (NYSE: COP), Suncor Energy (NYSE: SU), Americas Petrogas (BOE.V), and Octagon 88 (OTCBB: OCTX).
- [By Jonathan Yates]
"Octagon 88 has received confirmation of 1.6 billion billion barrels PIIP," was the headline for the press release dated September 11, 2013. Needless to say, Octagon 88 (OTCBB: OCTX), a small cap oil and natural gas exploration based in Switzerland with assets in the oil-rich Alberta province of Canada, has soared on that and other bullish news. From early July, the stock price for Octagon 88 just about doubled.
- [By Jonathan Yates]
It will also be bullish for publicly traded companies in each sector, ranging from prominent blue chips like Exxon Mobil (NYSE: XOM) and Goldcorp (NYSE: GG) to promising small caps like Octagon 88 (OTC: OCTX) and Wishbone Gold PLC (OTC: WISHY).
No comments:
Post a Comment